Effectiveness of butylphthalide on cerebral autoregulation in ischemic stroke patients with large artery atherosclerosis (EBCAS study): A randomized, controlled, multicenter trial
机构：[1]Stroke Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China[2]Neuroscience Research Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China[3]Department of Neurology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China[4]Department of Neurology, The People’s Hospital of Lixin County, Bozhou, China[5]Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[6]Laboratory for Engineering and Scientific Computing, Institute of Advanced Computing and Digital Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China[7]Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
Finding appropriate drugs to improve cerebral autoregulation (CA) in patients with acute ischemic stroke (AIS) is necessary to improve prognosis. We aimed to investigate the effect of butylphthalide on CA in patients with AIS. In this randomized controlled trial, 99 patients were 2:1 randomized to butylphthalide or placebo group. The butylphthalide group received intravenous infusion with a preconfigured butylphthalide-sodium chloride solution for 14 days and an oral butylphthalide capsule for additional 76 days. The placebo group synchronously received an intravenous infusion of 100 mL 0.9% saline and an oral butylphthalide simulation capsule. The transfer function parameter, phase difference (PD), and gain were used to quantify CA. The primary outcomes were CA levels on the affected side on day 14 and day 90. Eighty patients completed the follow-up (52 in the butylphthalide group and 28 in the placebo group). The PD of the affected side on 14 days or discharge and on 90 days was higher in the butylphthalide group than in the placebo group. The differences in safety outcomes were not significant. Therefore, butylphthalide treatment for 90 days can significantly improve CA in patients with AIS.
基金：
This project was supported by the National Natural
Science Foundation of China (Grant No. 81971105), the
Science and Technology Department of Jilin Province
(YDZJ202201ZYTS677), and Norman Bethune Program of
Jilin University (2022B02) to ZNG, and the National Key
R&D Program of China (2016YFC1301600), the Norman
Bethune Health Science Center of Jilin University
(2022JBGS03), Science and Technology Department of Jilin
Province (20220303002SF), and Jilin Provincial Key
Laboratory (YDZJ202302CXJD017) to YY.
第一作者机构：[1]Stroke Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China[2]Neuroscience Research Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China
通讯作者：
通讯机构：[1]Stroke Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China[*1]Stroke Center, Department of Neurology, The First Hospital of Jilin University, Xinmin Street 1#, Changchun 130021, China.
推荐引用方式(GB/T 7714)：
Guo Zhen-Ni,Yue Bing-Hong,Fan Lei,et al.Effectiveness of butylphthalide on cerebral autoregulation in ischemic stroke patients with large artery atherosclerosis (EBCAS study): A randomized, controlled, multicenter trial[J].JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM.2023,43(10):1702-1712.doi:10.1177/0271678X231168507.
APA：
Guo, Zhen-Ni,Yue, Bing-Hong,Fan, Lei,Liu, Jie,Zhu, Yuanyuan...&Yang, Yi.(2023).Effectiveness of butylphthalide on cerebral autoregulation in ischemic stroke patients with large artery atherosclerosis (EBCAS study): A randomized, controlled, multicenter trial.JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM,43,(10)
MLA：
Guo, Zhen-Ni,et al."Effectiveness of butylphthalide on cerebral autoregulation in ischemic stroke patients with large artery atherosclerosis (EBCAS study): A randomized, controlled, multicenter trial".JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 43..10(2023):1702-1712
医学